Pneumonitis in human cytomegalovirus infection

Current Infectious Disease Reports

Volumn 8, Issue 3, 2006, Pages 222-230

  Langhoff, Erik ^a   Siegel, Robert E ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CD39 ANTIGEN; CORTICOSTEROID DERIVATIVE; CYTOMEGALOVIRUS VACCINE; DNA POLYMERASE; DNA VACCINE; DOUBLE STRANDED DNA; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; LIVE VACCINE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; SUBUNIT VACCINE; TUMOR NECROSIS FACTOR ALPHA; VALGANCICLOVIR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ARTICLE; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; DIAGNOSTIC TEST; DISEASE EXACERBATION; DNA SYNTHESIS INHIBITION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG TARGETING; HUMAN; HUMAN CYTOMEGALOVIRUS; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMMUNE DEFICIENCY; IMMUNOREACTIVITY; INCIDENCE; KIDNEY FAILURE; LUNG TRANSPLANTATION; MACROPHAGE; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; MONOCYTE; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; RECIPIENT; RETINITIS; THROMBOCYTOPENIA; VIRUS INHIBITION; VIRUS PNEUMONIA; XENOTRANSPLANTATION;

EID: 33646769294     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-006-0063-z     Document Type: Article

References (90)

1. Riddell SR, Rabin M, Geballe AP, et al.: Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 1991, 146:2795-2804.
2. Yen KT, Lee AS, Krowka MJ, Burger CD: Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. Clin Chest Med 2004, 25:189-201.
3. Konoplev S, Champlin RE, Giralt S, et al.: Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow transplant 2001, 27:877-881.
4. Gerna G, Baldanti F, Revello MG: Pathogenesis of human cytomegalovirus infection and cellular targets. Hum Immunol 2004, 65:381-386.
5. Ljungman P, Griffiths P, Paya C: Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1047.
6. Ison MG, Fishman JA: Cytomegalovirus pneumonia in transplant recipients. Clin Chest Med 2005, 26:691-705.
7. Seehofer D, Rayes N, Neumann UP, et al.: Changing impact of cytomegalovirus in liver transplantation - a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis. Transpl Int 2005, 18:941-948.
8. Slifkin M, Ruthazer R, Freeman R, et al.: Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transpl 2005, 11:1597-1602.
9. Meyers JD: Infection in bone marrow transplant recipients. Am J Med 1986, 81:27-38.
10. McKenzie R, Travis WD, Dolan SA, et al.: The causes of death in patients with human immunodeficiency virus infection: a clinical and pathologic study with emphasis on the role of pulmonary diseases. Medicine (Baltimore) 1991, 70:326-343.
11. Crumpacker CS, Wadhwa S: Cytomegalovirus. In Principles and Practice of Infectious Diseases. Edited by Mandel GL, Bennett GE, Raphael D. Philadelphia: Elsevier, 2005:1786-1801.
12. Uberti-Foppa C, Lillo F, Terreni MR, et al.: Cytomegalovirus pneumonia in AIDS patients: value of cytomegalovirus culture from BAL fluid and correlation with lung disease. Chest 1998, 113:919-923.
13. Tamm M, Traenkle P, Grilli B, et al.: Pulmonary cytomegalovirus infection in immunocompromised patients. Chest 2001, 119:838-843.
14. Gasparetto EL, Ono SE, Escuissato D, et al.: Cytomegalovirus pneumonia after bone marrow transplantation: high resolution CT findings. Br J Radiol 2004, 77:724-727.
15. Franquet T, Lee KS, Muller NL: Thin-section CT findings in 32 immunocompromised patients with cytomegalovirus pneumonia who do not have AIDS. AJR Am J Roentgenol 2003, 181:1059-1063.
16. Najjar M, Siddiqui AK, Rossoff L, Cohen RI: Cavitary lung masses in SLE patients: an unusual manifestation of CMV infection. Eur Respir J 2004, 24:182-184.
17. Shimada A, Koga T, Shimada M, et al.: Cytomegalovirus pneumonitis presenting small nodular opacities. Intern Med 2004, 43:1198-1200.
18. Dunn W, Chou C, Li H, et al.: Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci U S A 2003, 100:14223-14228.
19. Sinzger C, Jahn G: Human cytomegalovirus cell tropism and pathogenesis. Intervirology 1996, 39:302-319.
20. Pignatelli S, Monte PD, Rossini G, Landini MP: Genetic polymorphims among human cytomegalovirus (HCVM) wild-typ strains. Rev Med Virol 2004, 14:383-410.
21. Hahn G, Revello MG, Patrone M, et al.: Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004, 78:10023-10033.
22. Ryckman BJ, Jarvis MA, Derek DD, et al.: Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol 2005, 80:710-722.
23. Wang D, Schenk T: Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 2005, 79:10330-10338.
24. Smith FB, Arias JH, Elmquist TH, Mazzara JT. Microvascular cytomegalovirus endothelialitis of the lung: a possible cause of secondary pulmonary hypertension in a patient with AIDS. Chest 1998, 114:337-340.
25. Waldman WJ, Knight DA, Huang EH, Sedmak DD: Bidirectional transmission of infectious cytomegalovirus between monocytes and vascular endothelial cells: an in vitro model. J Infect Dis 1995, 171:263-272.
26. Popa ER, Kas-Deelen AM, Hepkema BG, et al.: Donor-derived circulating endothelial cells after kidney transplantation. Transplantation 2002, 74:1320-1337.
27. Reinhardt B, Vaida B, Voisard R, et al.: Human cytomegalovirus infection in human renal arteries in vitro. J Virol Methods 2003, 109:1-9.
28. Kas-Deelen AM, Harmsen MC, De Maar EF, et al.: Acute rejection before cytomegalovirus infection enhances von Willebrand factor and soluble VCAM-1 in blood. Kidney Int 2000, 58:2533-2542.
29. Waldman WJ, Knight DA: Cytokine-mediated induction of endothelial adhesion molecule and histocompatibility leukocyte antigen expression by cytomegalovirus-activated T cells. Am J Pathol 1996, 148:105-119.
30. Sedmak DD, Knight DA, Vook NC, Waldman JW: Divergent patterns of ELAM-1, ICAM-1, and VCAM-1 expression on cytomegalovirus-infected endothelial cells. Transplantation 1994, 58:1379-1385.
31. Dengler TJ, Raftery MJ, Werle M, et al.: Cytomegalovirus infection of vascular cells induces expression of pro-inflammatory adhesion molecules by paracrine action of secreted interleukin-1beta. Transplantation 2000, 69:1160-1168.
32. Simon CO, Seckert CK, Dreis D, et al.: Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J Virol 2005, 79:326-340.
33. Hahn G, Khan H, Baldanti F, et al.: The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human cytomegalovirus with preserved wild-type characteristics. J Virol 2002, 76:9551-9555.
34. Brune W, Menard C, Heesemann J, Koszinowski UH: A ribonucleotide reductase homolog of cytomegalovirus and endothelial cell tropism. Science 2001, 291:303-305.
35. Skaletskaya A, Bartle LM, Chittenden T, et al.: A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc Natl Acad Sci U S A 2001, 98:7829-7834.
36. Goldmacher VS, Bartle LM, Skaletskaya A, et al.: A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. Proc Natl Acad Sci U S A 1999, 96:12536-12541.
37. Zhu H, Shen Y, Shenk T: Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J Virol 1995, 69:7960-7970.
38. Craigen JL, Grundy JE: Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Transplantation 1996, 62:1102-1108.
39. Kas-Deelen AM, Bakker WW, Olinga P, et al.: Cytomegalovirus infection increases the expression and activity of ecto-ATPase (CD39) and ecto-5′nucleotidase (CD73) on endothelial cells. FEBS Lett 2001, 491:21-25.
40. Reinhardt B, Schaarschmidt P, Bossert A, et al.: Upregulation of functionally active vascular endothelial growth factor by human cytomegalovirus. J Gen Virol 2005, 86:23-30.
41. Persoons MC, Stals FS, van dam Mieras MC, Bruggeman CA: Multiple organ involvement during experimental cytomegalovirus infection is associated with disseminated vascular pathology. J Pathol 1998, 184:103-109.
42. Crestani B, Aubier M: Inflammatory role of alveolar epithelial cells. Kidney Int Suppl 1998, 65:S88-S93.
43. Ng-Bautista CL, Sedmak DD: Cytomegalovirus infection is associated with absence of alveolar epithelial cell HLA class II antigen expression. J Infect Dis 1995, 171:39-44.
44. Langhoff E, Steinman RM: Clonal expansion of human T lymphocytes initiated by dendritic cells. J Exp Med 1989, 169:315-320.
45. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 1991:271-296.
46. Holt PG, Schon-Hegrad MA, Oliver J, et al.: A contiguous network of dendritic antigen-presenting cells within the respiratory epithelium. Int Arch Allergy Appl Immunol 1990, 91:155-159.
47. von Garnier C, Filgueira L, Wikstrom M, et al.: Anatomical location determines the distribution and function of dendritic cells and other APCs in the respiratory tract. J Immunol 2005, 175:1609-1618.
48. Webb TJ, Sumpter TL, Thiele AT, et al.: The phenotype and function of lung dendritic cells. Crit Rev Immunol 2005, 25:465-491.
49. Riegler S, Hebart H, Einsele H, et al.: Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J Gen Virol 2000, 81:393-399.
50. Gerna G, Percivalle E, Lilleri D, et al.: Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol 2005, 86:275-284.
51. Hertel L, Lacaille VG, Strobl H, et al.: Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus. J Virol 2003, 77:7563-7574.
52. Geijtenbeek TB, Torensma R, van Vliet SJ, et al.: Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000, 100:575-585.
53. Halary F, Amara A, Lortat-Jacob H, et al.: Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection. Immunity 2002, 17:653-664.
54. Geijtenbeek TB, Kwon DS, Torensma R, et al.: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597.
55. Carlsson B, Cheng WS, Totterman TH, Essand M: Ex vivo stimulation of cytomegalovirus (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators. Br J Haematol 2003, 121:428-438.
56. Bennekov T, Spector D, Langhoff E: Induction of immunity against human cytomegalovirus. Mt Sinai J Med 2004, 71:86-93.
57. Peggs K, Verfuerth S, Mackinnon S: Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 2001, 97:994-1000.
58. Trivedi D, Williams RY, O'Reilly RJ, Koehne G: Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood 2005, 105:2793-2801.
59. Carlsson B, Hou M, Giandomenico V, et al.: Simultaneous generation of cytomegalovirus-specific CD8+ and CD4+ T lymphocytes by use of dendritic cells comodified with pp65 mRNA and pp65 protein. J Infect Dis 2005, 192:1912-1920.
60. Heine A, Grunebach F, Holderried T, et al.: Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8(+)- and CD4(+)-mediated CMV-specific T cell responses. Mol Ther 2006, 13:280-288.
61. Jarvis MA, Nelson JA: Mechanisms of human cytomegalovirus persistence and latency. Front Biosci 2002, 7:1575-1582.
62. Stoddart CA, Cardin RD, Boname JM, et al.: Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus. J Virol 1994, 68:6243-6253.
63. Walter EA, Greenberg PD, Gilbert MJ, et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Eng J Med 1995, 333:1038-1044.
64. Riddell SR, Gilbert MJ, Li CR, et al.: Reconstitution of protective CD8+ cytotoxic T lymphocyte responses to human cytomegalovirus iln immundeficient humans by the adoptive transfer of T cell clones. In Mutidiciplinary Appoach to Understanding Cytomegalovirus Disease. Edited by Michelson S, Plotkin SA. Amsterdam: Elsevier Science; 1993:155-164.
65. Schleiss MR, Heineman TC: Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 2005, 4:381-406.
66. Stinski M: Sequence of protein synthesis in cells infected by human cytomegalo virus:Early and late virus-induced polypeptides. J Virol 1978, 26:686-696.
67. Schmolke S, Kern HF, Drescher P, et al.: The dominant phosphoprotein pp65 (UL83) of the human cytomegalovirus is dispensable for growth in cell culture. J Virol 1995, 69:5959-5968.
68. Wills MR, Carmichael AJ, Mynard K, et al.: The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T cell receptor usage of pp65-specific CTL. J Virol 1996, 70:7569-7579.
69. Diamond DJ, York J, Sun J-Y, et al.: Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997, 90:1751-1767.
70. Urban M, Britt W, Mach M: The dominant linearneutralizing antibody-binding site of glycoprotein gp86 of human cytmegalovirus is strain specific. J Virol 1992, 66:1303-1311.
71. Roy DM, Grundy JE, Emery VC: Sequence variation within neutralizing epitops of the envelope glycoprotein B of human cytomegalovirus. J Gen Virol 1993, 74:2499-2505.
72. Colimon R, Somogyi T, Bertrand C, Michelson S: Demonstration of the colinearity of human cytomegalovirus genomes and contruction of restriction maps of unknown isolates using cloned subgenomic fragments. J Gen Virol 1985, 66:2183-2198.
73. Mocarski ES: Cytomegaloviruses and their replication. In Virology, edn 2. Edited by Fields BN. Philadelphia: Lippincott-Raven Publishers; 1996:2447-2492.
74. Warren AP, DuCroq DH, Lehner PJ, Borusiewicz LK: Human cytomegalovirus-infected cells have unstable assembly of major hisotocompatibility complex class I complexes and are resistant to lysis by cytotoxic T lymphocytes. J Virol 1994, 68:2822.
75. Jones TR, Wiertz EJ, Sun L, et al.: Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A 1996, 93:11327-11333.
76. Hengel H, Flohr GJ, Hammerling GJ, et al.: Human cytomegalovirus inhibits peptide translocation into the endoplasmatic reticulum for MHC class I assembly. J Gen Virol 1996, 77:2287-2296.
77. Pleskoff O, Treboute C, Brelot A, et al.: Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science 1997, 276:1874-1878.
78. Rayburn HT, Dandeboim O, Vales-Gomez M, et al.: The class I HMC homologue of human cytomegalo virus inhibits attack by natural killer cells. Nature 1997, 386:514-517.
79. Greenberg PD, Reusser P, Goodrich JM, Riddell SR: Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor derived CMV specific T cell clones expanded in vitro. Ann NY Acad Sci 1991, 636:184-195.
80. Jonjic S, Pavic I, Polic B, et al.: Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrrent virus. J Exp Med 1994, 179:1713-1717.
81. Plotkin SA: Effect of Towne live virus vaccine on cotomegalovirus disease after renal transplantation. Ann Int Med 1991, 114:525-531.
82. Varga M, Remport A, Hidvegi M, et al.: Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience. Transpl Infect Dis 2005, 7:63-67.
83. Boeckh M, Gooley T, Goodrich J, et al.: Increased incidence of late cytomegalovirus disease in patients who received ganciclovir prohylaxis after allogeneic marrow transplantation. Paper presented at the Eighth International Symposium on Infections in the Immuno-compromised Host. Comstock, MI, 1994.
84. Goodrich JM, Bowden R, Fisher L, et al.: Ganciclovir prohylaxis to prevent cytomegalovirus disease diesease after allogenic marrow transplant. Ann Int Med 1993, 118:173-178.
85. Kalpoe JS, Schippers EF, Eling Y, et al.: Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation. Antivir Ther 2005, 10:119-123.
86. Limaye AP, Raghu G, Koelle DM, et al.: High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002, 185:20-27.
87. Degre M, Ranneberg-Nilsen T, Beck S, et al.: Human cytomegalovirus productively infects porcine endothelial cells in vitro. Transplantation 2001, 72:1334-1337.
88. Mueller NJ, Barth RN, Yamamoto S, et al.: Activation of cytomegalovirus in pig-to-primate organ xenotransplantation. J Virol 2002, 76:4734-4740.
89. Mueller NJ, Sulling K, Collackner B, et al.: Reduced efficacy of gangciclovir against porcine and baboon cytomegalovirus in pig-to-baboon xenotransplantation. Am J Transplantation 2003, 3:1057-1064.
90. Michaels MG, Jenkins FJ, St George K, et al.: Detection of infectious baboon cytomegalovirus after baboon-to-human liver xenotransplantation. J Virol 2001, 75:2825-2828.